
By BY PAM BELLUCK
The list price of the therapy, Relyvrio, is much higher than an economic research group recommends, but the company says most patients will pay very little themselves.
Published: September 30, 2022 at 04:16PM
from NYT Health https://ift.tt/lUoZhk3
via IFTTT
No comments:
Post a Comment